Cambridge biotech company sells for $1.6b
After British deal, TKT's CEO quits
One of the region's leading biotechnology companies said yesterday that it would be acquired by a British drug company for $1.6 billion, a decision that prompted the Cambridge company's chief executive to resign in protest. (Full article: 1109 words)
This article is available in our archives:
Globe Subscribers
FREE for subscribers
Subscribers to the Boston Globe get unlimited access to our archives.
Not a subscriber?
Non-Subscribers
Purchase an electronic copy of the full article. Learn More
- $9.95 1 month archives pass
- $24.95 3 months archives pass
- $74.95 1 year archives pass
Waiting for Twitter to feed in the latest...